Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation?
- 1 August 1999
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 14 (8) , 741-744
- https://doi.org/10.1046/j.1440-1746.1999.01962.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- C ASE R EPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapyJournal of Gastroenterology and Hepatology, 1999
- Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.Journal of Clinical Investigation, 1998
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantationBone Marrow Transplantation, 1998
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyHepatology, 1998
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.Journal of Clinical Investigation, 1992
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis BNew England Journal of Medicine, 1990
- Reactivation of Chronic Type B Hepatitis Presenting as Acute Viral HepatitisAnnals of Internal Medicine, 1985